Patents by Inventor Gary D. Tollefson

Gary D. Tollefson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Layered Pharmaceutical Formulations
    Publication number: 20230301922
    Abstract: In one embodiment a layered pharmaceutical formulation includes two or more pharmaceutical layers and an intermediate layer disposed between at least two of the two or more pharmaceutical layers, the intermediate layer configured to dissolve in vivo to thereby leave the two or more pharmaceutical layers substantially intact. In one embodiment, an active pharmaceutical ingredient in at least one of the pharmaceutical layers is selected from bupropion, zonisamide, naltrexone, topiramate, phentermine, metformin, olanzapine and fluoxetine.
    Type: Application
    Filed: May 4, 2023
    Publication date: September 28, 2023
    Applicant: Nalpropion Pharmaceuticals LLC
    Inventors: Anthony A. McKinney, Gary D. Tollefson, Eckard Weber, Richard Soltero
  • Methods for treating visceral fat conditions
    Patent number: 11324741
    Abstract: Disclosed are methods and compositions for treating visceral fat conditions and/or metabolic syndrome using combinations of naltrexone and bupropion.
    Type: Grant
    Filed: March 1, 2017
    Date of Patent: May 10, 2022
    Assignee: Nalpropion Pharmaceuticals LLC
    Inventor: Gary D. Tollefson
  • Compositions and Methods for Increasing Insulin Sensitivity
    Publication number: 20210346469
    Abstract: Methods and compositions for treating a blood glucose condition involve identifying a suitable subject and administering an effective amount of a composition that contains one or more of an opioid antagonist, an anticonvulsant, and a psychotherapeutic agent. The compositions can include insulin. In some embodiments, such methods and compositions can be used to modulate a blood glucose level. In preferred embodiments, such methods and compositions are useful for increasing a subject's sensitivity to insulin.
    Type: Application
    Filed: June 1, 2021
    Publication date: November 11, 2021
    Applicant: Nalpropion Pharmaceuticals LLC
    Inventors: Michael Alexander Cowley, Anthony A. McKinney, Gary D. Tollefson
  • Methods Of Providing Weight Loss Therapy In Patients With Major Depression
    Publication number: 20210299119
    Abstract: Disclosed are methods of providing weight loss therapy, particularly for patients suffering from major depression.
    Type: Application
    Filed: June 14, 2021
    Publication date: September 30, 2021
    Applicant: Nalpropion Pharmaceuticals LLC
    Inventors: Eduardo Dunayevich, Gary D. Tollefson
  • Compositions And Methods For Reducing Food Cravings
    Publication number: 20210267968
    Abstract: Disclosed are compositions for reducing food cravings, comprising a first compound and a second compound, where the first compound is an opioid antagonist and the second compound is an ?-MSH agonist. Also disclosed are methods of reducing food cravings, comprising identifying an individual in need thereof and treating that individual to antagonize opioid receptor activity and to enhance ?-MSH activity.
    Type: Application
    Filed: May 13, 2021
    Publication date: September 2, 2021
    Applicant: Nalpropion Pharmaceuticals LLC
    Inventors: Anthony A. McKinney, Gary D. Tollefson, Michael Alexander Cowley
  • Methods For Administering Weight Loss Medications
    Publication number: 20200352863
    Abstract: Methods and systems for administration of pharmaceuticals using a unit dosage package that includes a first unit dosage that has a first drug and a second drug, a second unit dosage that has the first drug and the second drug, where the second unit dosage includes a different amount of the second drug than the first unit dosage and a unit dosage package is configured to hold the first unit dosage and the second unit dosage. In preferred embodiments the methods and systems are used for administration of weight loss medications.
    Type: Application
    Filed: July 24, 2020
    Publication date: November 12, 2020
    Applicant: Naipropion Pharmaceuticals LLC
    Inventors: Anthony A. McKinney, Gary D. Tollefson, Eckard Weber, Richard Soitero
  • Compositions And Methods For Increasing Insulin Sensitivity
    Publication number: 20190231852
    Abstract: Methods and compositions for treating a blood glucose condition involve identifying a suitable subject and administering an effective amount of a composition that contains one or more of an opioid antagonist, an anticonvulsant, and a psychotherapeutic agent. The compositions can include insulin. In some embodiments, such methods and compositions can be used to modulate a blood glucose level. In preferred embodiments, such methods and compositions are useful for increasing a subject's sensitivity to insulin.
    Type: Application
    Filed: April 8, 2019
    Publication date: August 1, 2019
    Inventors: Michael Alexander Cowley, Anthony A. McKinney, Gary D. Tollefson
  • Methods of providing weight loss therapy in patients with major depression
    Patent number: 10322121
    Abstract: Disclosed are methods of providing weight loss therapy, particularly for patients suffering from major depression.
    Type: Grant
    Filed: January 29, 2016
    Date of Patent: June 18, 2019
    Assignee: Nalpropion Pharmaceuticals, Inc.
    Inventors: Eduardo Dunayevich, Gary D. Tollefson
  • METHODS FOR TREATING VISCERAL FAT CONDITIONS
    Publication number: 20170172999
    Abstract: Disclosed are methods and compositions for treating visceral fat conditions and/or metabolic syndrome using combinations of naltrexone and bupropion.
    Type: Application
    Filed: March 1, 2017
    Publication date: June 22, 2017
    Inventor: Gary D. Tollefson
  • COMPOSITIONS AND METHODS FOR INCREASING INSULIN SENSITIVITY
    Publication number: 20170020990
    Abstract: Methods and compositions for treating a blood glucose condition involve identifying a suitable subject and administering an effective amount of a composition that contains one or more of an opioid antagonist, an anticonvulsant, and a psychotherapeutic agent. The compositions can include insulin. In some embodiments, such methods and compositions can be used to modulate a blood glucose level. In preferred embodiments, such methods and compositions are useful for increasing a subject's sensitivity to insulin.
    Type: Application
    Filed: October 3, 2016
    Publication date: January 26, 2017
    Inventors: Michael A. Cowley, Anthony A. McKinney, Gary D. Tollefson
  • SUSTAINED RELEASE FORMULATION OF NALTREXONE
    Publication number: 20170014404
    Abstract: A sustained-release oral dosage form of naltrexone or a pharmaceutically acceptable salt thereof is provided. The oral dosage form may be administered with another compound. Administration of the oral dosage form may reduce a side effect, which may be a side effect at least partially attributable to a weight-loss treatment. The oral dosage form may be administered to treat a weight-loss condition.
    Type: Application
    Filed: September 28, 2016
    Publication date: January 19, 2017
    Inventors: Anthony A. McKinney, Gary D. Tollefson, Richard Soltero, Thea Elise Dunzo
  • LAYERED PHARMACEUTICAL FORMULATIONS
    Publication number: 20160338965
    Abstract: In one embodiment a layered pharmaceutical formulation includes two or more pharmaceutical layers and an intermediate layer disposed between at least two of the two or more pharmaceutical layers, the intermediate layer configured to dissolve in vivo to thereby leave the two or more pharmaceutical layers substantially intact. In one embodiment, an active pharmaceutical ingredient in at least one of the pharmaceutical layers is selected from bupropion, zonisamide, naltrexone, topiramate, phentermine, metformin, olanzapine and fluoxetine.
    Type: Application
    Filed: January 5, 2016
    Publication date: November 24, 2016
    Inventors: Anthony A. McKinney, Gary D. Tollefson, Eckard Weber, Rick Soltero
  • SUSTAINED RELEASE FORMULATION OF NALTREXONE
    Publication number: 20160158225
    Abstract: A sustained-release oral dosage form of naltrexone or a pharmaceutically acceptable salt thereof is provided. The oral dosage form may be administered with another compound. Administration of the oral dosage form may reduce a side effect, which may be a side effect at least partially attributable to a weight-loss treatment. The oral dosage form may be administered to treat a weight-loss condition.
    Type: Application
    Filed: February 17, 2016
    Publication date: June 9, 2016
    Inventors: Anthony A. McKinney, Gary D. Tollefson, Richard Soltero, Thea Elise Dunzo
  • SUSTAINED RELEASE FORMULATION OF NALTREXONE
    Publication number: 20160158221
    Abstract: A sustained-release oral dosage form of naltrexone or a pharmaceutically acceptable salt thereof is provided. The oral dosage form may be administered with another compound. Administration of the oral dosage form may reduce a side effect, which may be a side effect at least partially attributable to a weight-loss treatment. The oral dosage form may be administered to treat a weight-loss condition.
    Type: Application
    Filed: August 13, 2015
    Publication date: June 9, 2016
    Inventors: Anthony A. McKinney, Gary D. Tollefson, Richard Soltero, Thea Elise Dunzo
  • METHODS OF PROVIDING WEIGHT LOSS THERAPY IN PATIENTS WITH MAJOR DEPRESSION
    Publication number: 20160143903
    Abstract: Disclosed are methods of providing weight loss therapy, particularly for patients suffering from major depression.
    Type: Application
    Filed: January 29, 2016
    Publication date: May 26, 2016
    Inventors: Eduardo Dunayevich, Gary D. Tollefson
  • Sustained release formulation of naltrexone
    Patent number: 9107837
    Abstract: A sustained-release oral dosage form of naltrexone or a pharmaceutically acceptable salt thereof is provided. The oral dosage form may be administered with another compound. Administration of the oral dosage form may reduce a side effect, which may be a side effect at least partially attributable to a weight-loss treatment. The oral dosage form may be administered to treat a weight-loss condition.
    Type: Grant
    Filed: November 26, 2014
    Date of Patent: August 18, 2015
    Assignee: Orexigen Therapeutics, Inc.
    Inventors: Anthony A. McKinney, Gary D. Tollefson, Richard Soltero, Thea Elise Dunzo
  • METHODS FOR TREATING VISCERAL FAT CONDITIONS
    Publication number: 20150119417
    Abstract: Disclosed are methods and compositions for treating visceral fat conditions and/or metabolic syndrome using combinations of naltrexone and bupropion.
    Type: Application
    Filed: December 29, 2014
    Publication date: April 30, 2015
    Inventor: Gary D. Tollefson
  • SUSTAINED RELEASE FORMULATION OF NALTREXONE
    Publication number: 20150080424
    Abstract: A sustained-release oral dosage form of naltrexone or a pharmaceutically acceptable salt thereof is provided. The oral dosage form may be administered with another compound. Administration of the oral dosage form may reduce a side effect, which may be a side effect at least partially attributable to a weight-loss treatment. The oral dosage form may be administered to treat a weight-loss condition.
    Type: Application
    Filed: November 26, 2014
    Publication date: March 19, 2015
    Inventors: Anthony A. McKinney, Gary D. Tollefson, Richard Soltero, Thea Elise Dunzo
  • Sustained release formulation of naltrexone
    Patent number: 8916195
    Abstract: A sustained-release oral dosage form of naltrexone or a pharmaceutically acceptable salt thereof is provided. The oral dosage form may be administered with another compound. Administration of the oral dosage form may reduce a side effect, which may be a side effect at least partially attributable to a weight-loss treatment. The oral dosage form may be administered to treat a weight-loss condition.
    Type: Grant
    Filed: June 4, 2007
    Date of Patent: December 23, 2014
    Assignee: Orexigen Therapeutics, Inc.
    Inventors: Anthony A. McKinney, Gary D. Tollefson, Richard Soltero, Thea Elise Dunzo
  • Method for providing neuro-protective effects
    Publication number: 20030022889
    Abstract: The present invention provides a method for treating ALS and for providing a neuro-protective effect comprising administering a therapeutically effective of olanzapinc or a pharmaceutically acceptable salt or solvate thereof.
    Type: Application
    Filed: August 27, 2002
    Publication date: January 30, 2003
    Inventors: Franklin P. Bymaster, Gary D. Tollefson